NOBL vs XBI
ProShares S&P 500 Dividend Aristocrats ETF vs SPDR S&P Biotech ETF
- • NOBL pays a higher dividend yield (2.07%).
Side-by-side metrics
| Metric | NOBL | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.35% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.07% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $11.53B | $10.73B |
YTD return | 9.90% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.60 | 1.10 |
P/E ratio | 23.65 | — |
Last price | $56.46 | $164.01 |
Inception | — | — |
Issuer | ProShares | State Street |
NOBL top holdings
| CAT | Caterpillar Inc | 1.86% |
| WST | West Pharmaceutical Services Inc | 1.83% |
| SWK | Stanley Black & Decker Inc | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| BEN | Franklin Resources Inc | 1.71% |
| SJM | JM Smucker Co | 1.64% |
| HRL | Hormel Foods Corp | 1.63% |
| GWW | W.W. Grainger Inc | 1.62% |
| CAH | Cardinal Health Inc | 1.62% |
| ESS | Essex Property Trust Inc | 1.61% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About NOBL
NOBL (ProShares S&P 500 Dividend Aristocrats ETF) is S&P 500 names with 25+ years of dividend growth. Managed by ProShares, the fund carries $11.5B in assets under management, an expense ratio of 0.35%, a dividend yield of 2.07%. Its largest holding is Caterpillar Inc (CAT), which represents 1.9% of the portfolio. Real Estate is the fund's largest sector exposure at 4.5%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.